Rockeby granted US patent for candida detection kit

Rockeby biomed (ASX:RBY) has been awarded an additional US patent over its SysCan3 Hospital Test Kit for use in the diagnosis of candida infections such as systemic candidiasis and thrush.

The kit is a multi-well ELISA kit containing a specific antigen preparation from Candida albicans that enables standard serology laboratories to detect the presence of antibodies to candida in a biological sample within three hours -- this compares to current detection methods that use blood culture testing, which can take up to four days, according to Rockeby.

The specific antigen formulation, which is manufactured at Rockeby's laboratory in Perth, is the key intellectual property for the SysCan3 Hospital Test Kit and the subject of the US patent.

The new grant notice adds to the three territories that have already been granted for the patent.

Rockeby's technology and products are now covered by 10 families of patents/patent applications that are expected to provide protection until 2022.